ClonePix 2 Mammalian Colony Picker

Cell line development solutions with automated clone screening

The ClonePix™ 2 Mammalian Colony Picker is a fully automated system for the selection of high-value clones used in antibody discovery and cell line development. Hybridoma, CHO cells, and other cell types are imaged and selected based on user-defined parameters. Plate handling, barcode reading, and picking are all fully integrated. All data, including images, are saved for downstream analysis. The picker increases the probability of finding optimally produced cell lines and significantly reduces time and labor.

Applications of ClonePix 2 Mammalian Colony Picker

Antigen-Specific Screening

Antibody discovery typically refers to the screening and identification of specific antibodies that target an antigen molecule for the diagnosis and treatment of diseases. The specificity of the antibody is based on its ability to bind the epitope, a unique region on the antigen molecule. Therapeutic antibodies are typically monoclonal, single cell-derived and target a unique epitope region on the antigen. The ClonePix 2 System automates screening and rapid detection of antigen-specific clones from a heterogenous population of cells.

Antigen-Specific Screening

Antibody discovery typically refers to the screening and identification of specific antibodies that target an antigen molecule for the diagnosis and treatment of diseases. The specificity of the antibody is based on its ability to bind the epitope, a unique region on the antigen molecule. Therapeutic antibodies are typically monoclonal, single cell-derived and target a unique epitope region on the antigen. The ClonePix 2 System automates screening and rapid detection of antigen-specific clones from a heterogenous population of cells.

Cell Line Development

Cell line development is a critical step in the process of generating biopharmaceutical molecules, such as monoclonal antibodies. The process often begins with transfecting the host cell type with the DNA encoding the therapeutic protein of interest allowing for random or directed integration of target DNA into the host cell genome. Thousands of clones are screened to isolate the rare high producing cells, a manual and time-consuming process.

Cell Line Development

Cell line development is a critical step in the process of generating biopharmaceutical molecules, such as monoclonal antibodies. The process often begins with transfecting the host cell type with the DNA encoding the therapeutic protein of interest allowing for random or directed integration of target DNA into the host cell genome. Thousands of clones are screened to isolate the rare high producing cells, a manual and time-consuming process.

Cell surface expression screening

Many proteins that express to the surface of cells are targets for the discovery and development of biopharmaceuticals. For instance, G-protein coupled receptors (GPCRs) are the largest class of cell-surface proteins and are targets for almost 40% of existing drugs. Discovery and selection of high-value cell surface clones from a transfected pool of cells can be challenging. The ClonePix 2 System represents an automated method of screening large populations of cells that increases the probability of finding rare high-affinity binder or high producer.

Cell surface expression screening

Many proteins that express to the surface of cells are targets for the discovery and development of biopharmaceuticals. For instance, G-protein coupled receptors (GPCRs) are the largest class of cell-surface proteins and are targets for almost 40% of existing drugs. Discovery and selection of high-value cell surface clones from a transfected pool of cells can be challenging. The ClonePix 2 System represents an automated method of screening large populations of cells that increases the probability of finding rare high-affinity binder or high producer.

Clone productivity screening and titer

An important component in identifying high-value clones is determining productivity of single cell-derived colonies. Screening for productivity using traditional approaches is laborious and time consuming, generally consisting of a multistep process that involves isolating single cells from limiting dilution followed by assessment of titer using ELISA. The ClonePix 2 System combines single-cell isolation and productivity screening into a single step, resulting in dramatically shorter screening times and increased number of candidates. The high throughput Octet systems on the other hand provides a method for the rapid determination of titer that also dramatically shortens screening times.

Clone productivity screening and titer

An important component in identifying high-value clones is determining productivity of single cell-derived colonies. Screening for productivity using traditional approaches is laborious and time consuming, generally consisting of a multistep process that involves isolating single cells from limiting dilution followed by assessment of titer using ELISA. The ClonePix 2 System combines single-cell isolation and productivity screening into a single step, resulting in dramatically shorter screening times and increased number of candidates. The high throughput Octet systems on the other hand provides a method for the rapid determination of titer that also dramatically shortens screening times.

Hybridoma Screening

Antibody discovery typically refers to the screening and identification of monoclonal antibodies (mAbs) that target a specific epitope for the diagnosis and treatment of diseases. A common approach to generating monoclonal antibodies involves the fusion of a pre-mitotic cancer cell with a post-mitotic and terminal antibody-expressing B-cell from the spleen. The resulting fused cell is called a hybridoma and has the advantage of producing mAbs while dividing to regenerate itself. Screening hybridomas for binding specificity or productivity can be automated using the ClonePix 2 System.

Hybridoma Screening

Antibody discovery typically refers to the screening and identification of monoclonal antibodies (mAbs) that target a specific epitope for the diagnosis and treatment of diseases. A common approach to generating monoclonal antibodies involves the fusion of a pre-mitotic cancer cell with a post-mitotic and terminal antibody-expressing B-cell from the spleen. The resulting fused cell is called a hybridoma and has the advantage of producing mAbs while dividing to regenerate itself. Screening hybridomas for binding specificity or productivity can be automated using the ClonePix 2 System.

Monoclonality Assurance

Cell line development and assurance of monoclonality are critical steps in the process of generating biopharmaceutical molecules, such as monoclonal antibodies. A cell line can be established following the isolation of a single viable cell robustly expressing the protein of interest. A key milestone in this process is documenting evidence of clonality. Documentation of clonality is typically image-based, whereby an image of a single cell is produced and included in regulatory filings.

Monoclonality Assurance

Cell line development and assurance of monoclonality are critical steps in the process of generating biopharmaceutical molecules, such as monoclonal antibodies. A cell line can be established following the isolation of a single viable cell robustly expressing the protein of interest. A key milestone in this process is documenting evidence of clonality. Documentation of clonality is typically image-based, whereby an image of a single cell is produced and included in regulatory filings.

Maximize flexibility in application workflow and experimental design

&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;lt;p&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;gt;Your browser does not support iframes.&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;lt;/p&amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;amp;gt;